New drug combo shows promise against tough esophageal cancer
NCT ID NCT07244978
First seen Nov 25, 2025 · Last updated May 21, 2026 · Updated 23 times
Summary
This study tests whether adding the experimental drug Ivonescimab to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 49 adults with stage II to IVA cancer will receive the combination, then have surgery to remove the tumor. The main goal is to see if the cancer disappears completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.